Incyte Corporation has received $0.15 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 7 Financial Advisor in the Stock Trading Firms. Among 7 Analysts, Bottom line EPS Estimate for the current quarter is $0.08 while the top line estimate is $0.27 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -49.75%.
Incyte Corporation reported better than expected with a surprise EPS of % or $0.11 during its most recent quarterly earnings. The Actual EPS was $0.11 compared to the Estimated EPS of $0. Wilmington based Incyte Corporation Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Feb 14, 2017.
Incyte Corporation has a Price to Earnings ratio of 168.9 for the trailing twelve month period. The price to book ratio of the company for the most recent quarter is 60.08. For the Most Recent Fiscal Year, Incyte Corporation has a price to cash ratio of 404.33. For the Trailing twelve month period, company showed a Net Profit Margin of 14.71% and Return on Equity of the stock is 50.38%.
In the last quarter, Incyte Corporation reported Annual Earnings of $0.11. Based on the filings, last years Annual Earnings was, $0.05. The consensus estimate for current quarter is $0.15 and for the current fiscal year, the estimate is $0.62. For the Next fiscal year, the estimate is $1.36 based on the consensus.
Incyte Corporation (NASDAQ:INCY) : On Tuesday heightened volatility was witnessed in Incyte Corporation (NASDAQ:INCY) which led to swings in the share price. The stock opened for trading at $117.95 and hit $121.31 on the upside , eventually ending the session at $121.21, with a gain of 2.52% or 2.98 points. The heightened volatility saw the trading volume jump to 1,473,397 shares. The 52-week high of the share price is $124.87 and the company has a market cap of $22,834 million. The 52-week low of the share price is at $55 .
Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer.